Medacta Launches MiniMAX Hip Stem for U.S. Surgeons
Elizabeth Hofheinz, M.P.H., M.Ed. • Tue, November 7th, 2017
Medacta International, headquartered in Castel San Pietro, Switzerland, has announced the introduction of a new cementless stem called the MiniMAX Hip.
As the company wrote in its October 12, 2017 news release, the MiniMAX is “an anatomical cementless stem that is engineered to provide enhanced fit and fill in the metaphyseal femur by following the natural shape of the femoral canal with a unique curved design.” Meant for minimally invasive anterior and posterior hip replacement procedures, the product launch follows the first U.S. MiniMAX Hip surgery, successfully performed by David Scott, M.D., of Spokane, Washington.
“The MiniMAX Hip Stem is a very versatile product. It was built as an addition to the product range of stems and instruments dedicated to our AMIS (anterior minimally invasive surgical) approach to hip replacement, but it also works with posterior techniques, providing surgeons with even more flexibility,” said Francesco Siccardi, company executive vice president. “Our partners in Europe and Australia have had extremely positive experiences with the implant, and we’re excited to offer it as another option for surgeons in the United States.”
According to the news release, “The MiniMAX Hip Stem aims to reduce risk and postoperative pain for patients while making it easier for surgeons to introduce it into the femur. The MiniMAX’s lateral flare design minimizes fracture, and its nine degrees of neck anteversion can provide more joint stability and reduce the risk of dislocation. The short, thin tip with five degrees of curvature lowers the risk of thigh pain caused by distal interference. The implant’s proximal titanium plasma spray and hydroxyapatite coating provide enhanced proximal fixation.”
“I was impressed with how well the MiniMAX Hip Stem replicates the natural anatomy of the human hip, rather than having the patient’s anatomy conform to the shape of the implant, like many other popular models,” said Dr. Scott. “Pairing the MiniMAX with a minimally invasive approach made for an efficient, effective procedure and my patient is recovering well.”
Matt Delong, vice president of Medacta USA, told OTW, “We’re very happy with the initial interest in the MiniMAX in the U.S market. This product has been performing very well clinically since 2007 and we are confident that we are offering one of the best anatomic, metaphyseal-filling reduced-length femoral components available today. A significant portion of the surgeon population believes that a design that follows the natural shape of the femoral anatomy is ideal for their patients, and that’s exactly what we have designed with the MiniMax.”